AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25587040 — intervention group
Group type: COMPARATOR
Intervention: No SCT
Number of subjects: 522
Study 25589001 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (>1 BMI unit)
Number of subjects: 7169
Study 25589001 — intervention group
Group type: COMPARATOR
Intervention: Stable weight (+/- 1 BMI unit)
Number of subjects: 7169
Study 25589001 — intervention group
Group type: COMPARATOR
Intervention: Weight loss (<1 BMI unit)
Number of subjects: 7169
Study 25589001 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline overweight
Number of subjects: 7169
Study 25589001 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline obesity
Number of subjects: 7169
Study 25589197 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus ICD therapy in REFINE-ICD
Number of subjects: 1001
Study 25589197 — intervention group
Group type: COMPARATOR
Intervention: Usual care in REFINE-ICD
Number of subjects: 1001
Study 25589197 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DM in ARTEMIS
Number of subjects: 1001
Study 25589197 — intervention group
Group type: COMPARATOR
Intervention: Patients without DM in ARTEMIS
Number of subjects: 1001
Study 25589197 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LVEF < 50% in ARTEMIS
Number of subjects: 1001
Study 25589197 — intervention group
Group type: COMPARATOR
Intervention: Patients with LVEF ≥ 50% in ARTEMIS
Number of subjects: 1001
Study 25589197 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LVEF below the median of 42% in REFINE-ICD
Number of subjects: 1001
Study 25589197 — intervention group
Group type: COMPARATOR
Intervention: Patients with LVEF above the median of 42% in REFINE-ICD
Number of subjects: 1001
Study 25589213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (weight reduction)
Number of subjects: 72
Study 25589626 — intervention group
Group type: EXPERIMENTAL
Intervention: ChiLob7/4 (agonistic anti-CD40 antibody) at 200 mg × 4 doses, administered by IV infusion weekly for 4 doses.
Number of subjects: 28
Study 25589626 — intervention group
Group type: EXPERIMENTAL
Intervention: ChiLob7/4 (agonistic anti-CD40 antibody) at doses above 16 mg.
Number of subjects: 28
Study 25589626 — intervention group
Group type: EXPERIMENTAL
Intervention: ChiLob7/4 (agonistic anti-CD40 antibody) at doses between 1.6 mg and 50 mg.
Number of subjects: 28
Study 25589626 — intervention group
Group type: EXPERIMENTAL
Intervention: ChiLob7/4 (agonistic anti-CD40 antibody) at doses that can be administered safely.
Number of subjects: 28
Study 25589626 — intervention group
Group type: EXPERIMENTAL
Intervention: ChiLob7/4 (agonistic anti-CD40 antibody) at doses from 50 mg upward.
Number of subjects: 28
Study 25590177 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic-controlled capsule endoscopy (MCE)
Number of subjects: 68
Study 25590177 — intervention group
Group type: COMPARATOR
Intervention: Gastroscopy
Number of subjects: 68
Study 25590214 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial norepinephrine concentration
Number of subjects: 58
Study 25590214 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated norepinephrine spillover rate
Number of subjects: 58
Study 25590214 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation index (AI)
Number of subjects: 58
Study 25590214 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity (M)
Number of subjects: 58
Study 25590214 — intervention group
Group type: EXPERIMENTAL
Intervention: Matsuda insulin sensitivity index
Number of subjects: 58
Study 25590214 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac output
Number of subjects: 58
Study 25590214 — intervention group
Group type: COMPARATOR
Intervention: Gender (female)
Number of subjects: 58
Study 25590481 — intervention group
Group type: EXPERIMENTAL
Intervention: probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 6
Study 25590481 — intervention group
Group type: COMPARATOR
Intervention: whole-lung lavage
Number of subjects: 6
Study 25590835 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day) and capecitabine (1000 mg/m2 twice daily on days 1-14)
Number of subjects: 58
Study 25590835 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus capecitabine
Number of subjects: 58
Study 25591040 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 0.9 mg/m2 on day 1 and gemcitabine 700 mg/m2 on days 1 + 8, every 3 weeks
Number of subjects: 5
Study 25591040 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 0.7 mg/m2 plus gemcitabine 700 mg/m2
Number of subjects: 5
Study 25591505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ledipasvir for 12 weeks
Number of subjects: 60
Study 25591505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir, ledipasvir, and GS-9669 for 6 weeks
Number of subjects: 60
Study 25591505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir, ledipasvir, and GS-9451 for 6 weeks
Number of subjects: 60
Study 25592331 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen (800 mg) administered over 5 to 10 minutes preoperatively
Number of subjects: 300
Study 25592341 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroid treatment
Number of subjects: 38
Study 25592341 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroids
Number of subjects: 38
Study 25592632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg orally once a day in 6-week cycles (4 weeks of treatment followed by 2 weeks without treatment)
Number of subjects: 41
Study 25592632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 41
Study 25592642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-screening during multidisciplinary cancer (MDC) meetings
Number of subjects: 4
Study 25592642 — intervention group
Group type: EXPERIMENTAL
Intervention: Final review by the principal investigator (PI)
Number of subjects: 4
Study 25592642 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic review by the clinical research assistant (CRA)
Number of subjects: 4
Study 25592642 — intervention group
Group type: COMPARATOR
Intervention: MDC reports
Number of subjects: 4
Study 25592642 — intervention group
Group type: COMPARATOR
Intervention: CRA proposals
Number of subjects: 4
Study 25592642 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposal by the PI
Number of subjects: 4
Study 25592642 — intervention group
Group type: COMPARATOR
Intervention: Proposal by the CRA
Number of subjects: 4
Study 25592691 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA with atherosclerotic plaque characteristics (APCs) including %APV, PR, LAP, SC
Number of subjects: 252
Study 25592691 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive remodeling (PR)
Number of subjects: 252
Study 25592691 — intervention group
Group type: EXPERIMENTAL
Intervention: Low attenuation plaque (LAP)
Number of subjects: 252
Study 25592691 — intervention group
Group type: EXPERIMENTAL
Intervention: Spotty calcification (SC)
Number of subjects: 252
Study 25592691 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or more APCs
Number of subjects: 252
Study 25592691 — intervention group
Group type: EXPERIMENTAL
Intervention: %APV and APCs by coronary CTA
Number of subjects: 252
Study 25592974 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium ionophore activation combined with ICSI; oocytes stimulated with calcium ionophore for 30 minutes after ICSI.
Number of subjects: 2
Study 25592974 — intervention group
Group type: COMPARATOR
Intervention: Non-activated oocytes (control group).
Number of subjects: 2
Study 25593047 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI cue-reactivity in the ventral striatum (VS)
Number of subjects: 49
Study 25593047 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI cue-reactivity in the orbitofrontal cortex (OFC)
Number of subjects: 49
Study 25593047 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-aggregation measures that consider both spatial extent and intensity of cue-induced brain activation
Number of subjects: 49
Study 25593047 — intervention group
Group type: EXPERIMENTAL
Intervention: Measure defined as the sum of t-values exceeding an individually defined threshold
Number of subjects: 49
Study 25593047 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collected in the VS
Number of subjects: 49
Study 25593079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal injection of CD133-positive enriched bone marrow progenitor cells
Number of subjects: 12
Study 25593211 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Kidney Injury (AKI)
Number of subjects: 615
Study 25593211 — intervention group
Group type: COMPARATOR
Intervention: Coronary angiographic procedures
Number of subjects: 615
Study 25593211 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline variables (creatinine clearance and left ventricular ejection fraction)
Number of subjects: 615
Study 25593211 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI
Number of subjects: 615
Study 25593303 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate and prednisone
Number of subjects: 348
Study 25593303 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 348
Study 25593740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived human mesenchymal stem/stromal cells (MSCs)
Number of subjects: 69
Study 25593740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 25593749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation with high PEEP
Number of subjects: 30
Study 25593749 — intervention group
Group type: COMPARATOR
Intervention: Control group with lower PEEP strategy
Number of subjects: 30
Study 25593749 — intervention group
Group type: EXPERIMENTAL
Intervention: NMB use
Number of subjects: 30
Study 25593749 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician comfort assessment
Number of subjects: 30
Study 25594553 — intervention group
Group type: EXPERIMENTAL
Intervention: FCRx (facilitating cell enriched hematopoietic stem cell allografts)
Number of subjects: 19
Study 25594553 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppression (IS)
Number of subjects: 19
Study 25594553 — intervention group
Group type: COMPARATOR
Intervention: Transient or nonchimeric status
Number of subjects: 19
Study 25594861 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) treatment for 0.8 years (median 0.5; 1.3)
Number of subjects: 287
Study 25594861 — intervention group
Group type: EXPERIMENTAL
Intervention: Puberty nomogram
Number of subjects: 287
Study 25594886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcoidosis Assessment Tool (SAT)
Number of subjects: 173
Study 25595221 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA treatment, mean dose 189.8 ± 87.1U, average treatment intervals of 14.6 and 15.1 weeks.
Number of subjects: 1046
Study 25595221 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA treatment
Number of subjects: 1046
Study 25595302 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 250
Study 25595315 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 75
Study 25595400 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenestrated/branched repair techniques
Number of subjects: 49
Study 25595936 — intervention group
Group type: COMPARATOR
Intervention: HOXB13 G84E variant in PrCa cases (1.5%) vs healthy controls (0.5%)
Number of subjects: 13904
Study 25595936 — intervention group
Group type: COMPARATOR
Intervention: Family history of PrCa
Number of subjects: 13904
Study 25595936 — intervention group
Group type: COMPARATOR
Intervention: Young-onset PrCa (diagnosed up to age 55)
Number of subjects: 13904
Study 25595936 — intervention group
Group type: COMPARATOR
Intervention: HOXB13 G84E variant
Number of subjects: 13904
Study 25595936 — intervention group
Group type: COMPARATOR
Intervention: Polygenic PrCa risk score (PR score) including HOXB13 G84E variant
Number of subjects: 13904
Study 25596263 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat 200 mg orally twice daily on days 1-14 and rituximab 375 mg/m² intravenously on day 1 of a 21-day cycle.
Number of subjects: 28
Study 25596263 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat/rituximab regimen
Number of subjects: 28
Study 25596264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 103
Study 25596270 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib
Number of subjects: 0
Study 25596270 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bortezomib
Number of subjects: 0
Study 25596313 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV) 150mg QD + peginterferon-α-2a/ribavirin (PR) for 12 weeks, followed by PR alone for 12 or 36 weeks.
Number of subjects: 107
Study 25596730 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavopiridol
Number of subjects: 0
Study 25596730 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of Mcl-1
Number of subjects: 0
Study 25599334 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA assessed via SenseWear Armband (MVPAOBJ)
Number of subjects: 448
Study 25599334 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported MVPA via Paffenbarger Questionnaire (MVPAPAFF)
Number of subjects: 448
Study 25599334 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported MVPA via Global Physical Activity Questionnaire (GPAQ)
Number of subjects: 448
Study 25599334 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported MVPA from transportation and recreation (MVPAGPAQ-REC)
Number of subjects: 448
Study 25599347 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART initiated during pregnancy
Number of subjects: 671
Study 25599347 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART initiated in the third trimester
Number of subjects: 671
Study 25599347 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparity
Number of subjects: 671
Study 25599347 — intervention group
Group type: EXPERIMENTAL
Intervention: Black ethnicity
Number of subjects: 671
Study 25599347 — intervention group
Group type: EXPERIMENTAL
Intervention: 11th grade education or less
Number of subjects: 671
Study 25599347 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV diagnosis before current pregnancy
Number of subjects: 671
Study 25599347 — intervention group
Group type: EXPERIMENTAL
Intervention: First prenatal visit in the third trimester
Number of subjects: 671
Study 25599347 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment interruptions or poor medication adherence
Number of subjects: 671
Study 25599365 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 25599695 — intervention group
Group type: EXPERIMENTAL
Intervention: Crush the Crave mobile phone app
Number of subjects: 1354
Study 25599695 — intervention group
Group type: COMPARATOR
Intervention: On the Road to Quitting self-help guide
Number of subjects: 1354
Study 25599806 — intervention group
Group type: EXPERIMENTAL
Intervention: Foetuses with congenital heart disease (CHD)
Number of subjects: 92
Study 25599806 — intervention group
Group type: COMPARATOR
Intervention: Foetuses with normal anatomy (Control)
Number of subjects: 92
Study 25599824 — intervention group
Group type: EXPERIMENTAL
Intervention: PGS using comprehensive chromosome screening after blastocyst biopsy (PGS-v2)
Number of subjects: 3
Study 25599824 — intervention group
Group type: COMPARATOR
Intervention: Routine IVF care
Number of subjects: 3
Study 25600030 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS women (lean)
Number of subjects: 300
Study 25600030 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese PCOS patients (all phenotypes)
Number of subjects: 300
Study 25600030 — intervention group
Group type: COMPARATOR
Intervention: PCOS women (all phenotypes)
Number of subjects: 300
Study 25600030 — intervention group
Group type: COMPARATOR
Intervention: Evaluated CVD risk (all phenotypes)
Number of subjects: 300
Study 25600030 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 of 4 Rotterdam phenotypes
Number of subjects: 300
Study 25600335 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenestrated/branched endovascular repair
Number of subjects: 924
Study 25603113 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral washes (OW)
Number of subjects: 56
Study 25603113 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputa (IS)
Number of subjects: 56
Study 25603113 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavages (BAL)
Number of subjects: 56
Study 25603463 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 11
Study 25603819 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (dose range 0.3-1.8 mg)
Number of subjects: 13
Study 25603819 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 13
Study 25603823 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated interferon-α (IFNα) levels in SLE patients with poor pregnancy outcomes
Number of subjects: 28
Study 25603823 — intervention group
Group type: EXPERIMENTAL
Intervention: Low IFNα levels in SLE patients
Number of subjects: 28
Study 25603823 — intervention group
Group type: EXPERIMENTAL
Intervention: High IFNα levels in SLE patients
Number of subjects: 28
Study 25603823 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IFNα and soluble Flt-1
Number of subjects: 28
Study 25603823 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble Flt-1 treatment on human endothelial cells
Number of subjects: 28
Study 25603822 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboxone 2.0/0.5-mg tablet
Number of subjects: 43
Study 25604319 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher knee OA x-ray grade
Number of subjects: 518
Study 25604319 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in clinical scores
Number of subjects: 518
Study 25604779 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral nutritional supplements (ingestion of ⩾ 11/15 units)
Number of subjects: 141
Study 25604779 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral nutritional supplements
Number of subjects: 141
Study 25605003 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 56
Study 25605003 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab treatment
Number of subjects: 56
Study 25605368 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab (1.0 mg/kg)
Number of subjects: 41
Study 25605368 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab (0.1, 0.3, and 1.0 mg/kg)
Number of subjects: 41
Study 25605552 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily trientine (15 mg/kg)
Number of subjects: 8
Study 25605745 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin at a dose of 14 mg/m(2) on days 1, 8, and 15 of 28-day cycles
Number of subjects: 130
Study 25605745 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin treatment
Number of subjects: 130
Study 25605853 — intervention group
Group type: EXPERIMENTAL
Intervention: Early screening MRI at 6.5 and 9 months from diagnosis
Number of subjects: 498
Study 25605853 — intervention group
Group type: EXPERIMENTAL
Intervention: Early screening MRI
Number of subjects: 498
Study 25605857 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Residual Disease (MRD) assessment at days +30, +60, +90, +180, and +365 after transplantation
Number of subjects: 113
Study 25605857 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD assessment
Number of subjects: 113
Study 25605857 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD ≥ 10(-4) leukemic cells
Number of subjects: 113
Study 25605857 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD detection
Number of subjects: 113
Study 25608607 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis in high-risk patients (Geneva Risk Score ≥ 3 points)
Number of subjects: 1478
Study 25608607 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis in low-risk patients (Geneva Risk Score < 3 points)
Number of subjects: 1478
Study 25608692 — intervention group
Group type: EXPERIMENTAL
Intervention: Alive-PD program (1-year, fully automated behavior change program delivered by email and Web)
Number of subjects: 340
Study 25608692 — intervention group
Group type: EXPERIMENTAL
Intervention: Alive-PD program
Number of subjects: 340
Study 25608692 — intervention group
Group type: COMPARATOR
Intervention: Delayed-entry control group
Number of subjects: 340
Study 25609248 — intervention group
Group type: EXPERIMENTAL
Intervention: OPB-51602 at 5 mg intermittently
Number of subjects: 51
Study 25609248 — intervention group
Group type: EXPERIMENTAL
Intervention: OPB-51602 at 4 mg continuously
Number of subjects: 51
Study 25609248 — intervention group
Group type: EXPERIMENTAL
Intervention: OPB-51602 at 4 mg intermittently (Cohort B)
Number of subjects: 51
Study 25609248 — intervention group
Group type: EXPERIMENTAL
Intervention: OPB-51602 at 2 mg and 4 mg intermittently
Number of subjects: 51
Study 25609248 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous dosing of OPB-51602
Number of subjects: 51
Study 25609248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dosing of OPB-51602
Number of subjects: 51
Study 25609248 — intervention group
Group type: EXPERIMENTAL
Intervention: OPB-51602
Number of subjects: 51
Study 25609320 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (300 mg on day 1, 600 mg on day 2, adjusted to 400-800 mg thereafter)
Number of subjects: 61
Study 25609320 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 61
Study 25609333 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-inhibitor (Berinert) as on-demand therapy
Number of subjects: 135
Study 25609333 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-inhibitor (Berinert) for prophylactic administration
Number of subjects: 135
Study 25609333 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-inhibitor (Berinert) in home setting
Number of subjects: 135
Study 25609333 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-inhibitor (Berinert) overall safety
Number of subjects: 135
Study 25609333 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-inhibitor (Berinert) thromboembolic events
Number of subjects: 135
Study 25609333 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-inhibitor (Berinert) safety profile
Number of subjects: 135
Study 25609353 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine treatment during positive OFCs
Number of subjects: 74